EAN 2021: Erenumab Outperforms Standard-of-Care Topiramate in Preventive Treatment of Episodic Migraine
Quality-of-life assessments also favored erenumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.